Current News

Contact | Print version | Send article | RSS feed

Lonza Awarded Commercial Manufacturing Agreement with Altus Pharmaceuticals

21 Nov 2006 - Lonza Group Ltd announced that an agreement with Altus Pharmaceuticals Inc. has been signed, whereby Lonza is granted long term manufacturing rights for Altus' ALTU-135 drug substances. All related production will be conducted in Lonza's FDA registered facility in Kouím, Czech Republic. The scope of manufacturing agreement includes microbial fermentation, process optimization, technical and regulatory support. In conjunction with the project, Lonza plans to enhance its down-stream processing competencies and hire additional skilled employees for the Kouím facility.
 
ALTU-135 was developed by Altus and is an orally administered enzyme replacement therapy for patients with pancreatic insufficiency. Altus plans initiating Phase III clinical trial in 2007, and preparations with Lonza are underway for a successful commercial launch.